同和药业
(300636)
| 流通市值：27.77亿 | | | 总市值：31.75亿 |
| 流通股本：3.67亿 | | | 总股本：4.20亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 306,214,227.3 | 176,384,468.01 | 132,148,876.62 | 421,145,881.9 |
| 应收票据及应收账款 | 102,502,602.54 | 94,676,422.41 | 106,289,452.65 | 108,454,027.05 |
| 应收账款 | 102,502,602.54 | 94,676,422.41 | 106,289,452.65 | 108,454,027.05 |
| 应收款项融资 | 3,838,650.8 | 1,814,625 | 3,556,921.31 | 98,353.95 |
| 预付款项 | 3,485,097.66 | 1,780,859.58 | 9,850,061.64 | 12,828,996.37 |
| 其他应收款合计 | 2,661,446.44 | 2,304,641.95 | 2,598,963 | 3,448,391.18 |
| 存货 | 556,947,024.81 | 552,510,646.85 | 561,229,478.14 | 526,060,357.7 |
| 一年内到期的非流动资产 | 183,118,290.14 | 194,583,071.91 | 175,808,618.2 | 153,086,845.96 |
| 其他流动资产 | 5,468,643.46 | 6,925,401.35 | 3,955,995.17 | 6,035,178.57 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,164,235,983.15 | 1,051,029,837.06 | 995,438,366.73 | 1,261,158,032.68 |
| 非流动资产: | | | | |
| 其他债权投资 | 672,688,308.26 | 721,223,641.59 | 769,390,590.57 | 525,730,562.81 |
| 长期股权投资 | 3,074,469.88 | 3,191,624.61 | 3,223,395.04 | 3,253,298.99 |
| 固定资产 | 1,171,530,990.5 | 1,301,979,988.18 | 1,328,414,924.76 | 1,351,288,668.88 |
| 在建工程 | 337,210,135.83 | 186,230,873.52 | 169,484,619.37 | 162,893,796.35 |
| 使用权资产 | 1,768,475.16 | 1,980,692.16 | 2,192,909.16 | 2,405,126.16 |
| 无形资产 | 19,070,627.67 | 19,282,512.03 | 19,483,916.03 | 19,711,520.93 |
| 递延所得税资产 | 229,341.57 | 109,864.64 | 140,372.78 | 284,837.5 |
| 其他非流动资产 | 51,478,854.41 | 34,522,638.92 | 7,315,752.44 | 3,308,030.9 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,257,051,203.28 | 2,268,521,835.65 | 2,299,646,480.15 | 2,068,875,842.52 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,421,287,186.43 | 3,319,551,672.71 | 3,295,084,846.88 | 3,330,033,875.2 |
| 流动负债: | | | | |
| 短期借款 | 383,647,711.75 | 300,799,776.66 | 329,428,036.67 | 433,656,146.21 |
| 应付票据及应付账款 | 155,911,869.92 | 150,358,272.11 | 143,246,596.11 | 107,939,707.77 |
| 其中：应付票据 | 79,318,166.73 | 98,870,916.09 | 82,294,855.66 | 44,892,034.76 |
| 应付账款 | 76,593,703.19 | 51,487,356.02 | 60,951,740.45 | 63,047,673.01 |
| 合同负债 | 7,208,685.72 | 4,238,510.72 | 5,658,642.4 | 2,998,165.35 |
| 应付职工薪酬 | 17,059,742.14 | 21,479,765.02 | 19,510,906.31 | 18,586,352.26 |
| 应交税费 | 1,580,882.35 | 2,119,759.23 | 1,670,477.91 | 1,942,573.18 |
| 其他应付款合计 | 20,330,691.47 | 24,423,078.53 | 18,937,738.4 | 16,043,307.14 |
| 一年内到期的非流动负债 | 2,020,479.89 | 2,422,259.14 | 17,928,640.13 | 17,928,640.13 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 587,760,063.24 | 505,841,421.41 | 536,381,037.93 | 599,094,892.04 |
| 非流动负债: | | | | |
| 长期借款 | 398,000,000 | 398,500,000 | 398,500,000 | 399,000,000 |
| 租赁负债 | 872,887.2 | 1,032,407.27 | 1,291,616.52 | 1,532,896.41 |
| 递延收益 | 60,818,579.84 | 62,349,556.1 | 3,894,782.36 | 3,938,508.62 |
| 递延所得税负债 | 44,306,393.35 | 43,080,402.1 | 45,651,943.88 | 44,503,759.76 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 503,997,860.39 | 504,962,365.47 | 449,338,342.76 | 448,975,164.79 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,091,757,923.63 | 1,010,803,786.88 | 985,719,380.69 | 1,048,070,056.83 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 421,527,350 | 421,527,350 | 421,527,350 | 421,527,350 |
| 资本公积 | 1,251,967,545.09 | 1,251,967,545.09 | 1,263,565,976.67 | 1,262,348,768.05 |
| 减:库存股 | 12,343,230.3 | 12,343,230.3 | 12,343,230.3 | 12,343,230.3 |
| 盈余公积 | 72,343,935.93 | 72,343,935.93 | 61,712,424.6 | 61,712,424.6 |
| 未分配利润 | 596,033,662.08 | 575,252,285.11 | 574,902,945.22 | 548,718,506.02 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,329,529,262.8 | 2,308,747,885.83 | 2,309,365,466.19 | 2,281,963,818.37 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,329,529,262.8 | 2,308,747,885.83 | 2,309,365,466.19 | 2,281,963,818.37 |
| 负债和股东权益合计 | 3,421,287,186.43 | 3,319,551,672.71 | 3,295,084,846.88 | 3,330,033,875.2 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-24 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |